The prognostic importance of double-expressor subgroup and AID, UNG and mismatch repair protein expressions in diffuse large B-cell lymphomas
Objective: The cases of diffuse large B-cell lymphoma, (DLBCL not otherwise specified (NOS)) which immunohistochemicallyexhibit MYC and BCL2 expressions are defined as double-expressor lymphomas (DELs). This study aimed to assess the prognosticimpact of DEL and the expressions of other proteins that may have role in tumorogenesis.Materials and Methods: In this study, 90 tumor samples from patients diagnosed with DLBCL NOS were evaluated retrospectively.Immunoexpressions of MYC, BCL2, activation-induced cytidine deaminase (AID), uracil-DNA glycosylase (UNG) and DNAmismatch repair proteins including MLH1, MSH2, MSH6 and PMS2 were analyzed.Result: Eleven cases (12.2%) which exhibited ≥40% MYC and ≥50% BCL2 immunexpressions were classified as DEL DLBCL. Patientswith MYC positivity displayed lower overall survival rate than MYC negative cases. A trend of lower overall survival was observed inthe double-expressor lymphoma group, however, this was not proven to be statistically significant. Significant relationship betweenAID, UNG and p53 immunexpressions with double-expressor lymphoma or overall survival was not detected. The correlationbetween immunexpressions of p53 and MYC was observed. The loss of expression of mismatch repair proteins was not observed inany cases.Conclusion: In this study, a relationship between low overall survival and MYC expression is detected. However, our result does notdemonstrate that double-expressor lymphoma can be associated with poor outcomes.
___
- [1] Schmidt MT, Huang Q, Alkan S. Aggressive B-cell lymphomas:
a review and practical approach for the practicing pathologist.
Adv Anatomic Pathol 2015;22:168-80. doi: 10.1097/
PAP.000.000.0000000065
- [2] Anderson JR, Armitage JO, Weisenburger DD. Epidemiology
of the non-Hodgkin’s lymphomas: distributions of the major
subtypes differ by geographic locations. Non-Hodgkin’s
Lymphoma Classification Project. Ann Oncol 1998;9:717-20.
doi: 10.1023/a:100.826.5532487
- [3] Swerdlow SH. WHO classification of tumours of
haematopoietic and lymphoid tissues. Lyon: International
Agency for Research on Cancer; 2017.
- [4] Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2
protein coexpression contributes to the inferior survival of
activated B-cell subtype of diffuse large B-cell lymphoma
and demonstrates high-risk gene expression signatures: a
report from The International DLBCL Rituximab-CHOP
Consortium Program. Blood 2013;121:4021-31; quiz 250. doi:
10.1182/blood-2012-10-460063
- [5] Johnson NA, Slack GW, Savage KJ, et al. Concurrent
expression of MYC and BCL2 in diffuse large B-cell lymphoma
treated with rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone. J Clin Oncol 2012;30:3452-9. doi:
10.1200/JCO.2011.41.0985
- [6] Green TM, Young KH, Visco C, et al. Immunohistochemical
double-hit score is a strong predictor of outcome in patients
with diffuse large B-cell lymphoma treated with rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone.
J Clin Oncol 2012;30:3460-7. doi: 10.1200/JCO.2011.41.4342
- [7] Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and
BCL2 protein expression predicts survival in patients with
diffuse large B-cell lymphoma treated with rituximab. Br J
Haematol 2014;165:382-91. doi: 10.1111/bjh.12763
- [8] Salles G, de Jong D, Xie W, et al. Prognostic significance of
immunohistochemical biomarkers in diffuse large B-cell
lymphoma: a study from the Lunenburg Lymphoma
Biomarker Consortium. Blood 2011;117:7070-8. doi: 10.1182/
blood-2011-04-345256
- [9] Greiner A, Tobollik S, Buettner M, et al. Differential expression
of activation-induced cytidine deaminase (AID) in nodular
lymphocyte-predominant and classical Hodgkin lymphoma.
J Pathol 2005;205:541-7. doi: 10.1002/path.1746
- [10] Ramiro AR, Jankovic M, Callen E, et al. Role of genomic
instability and p53 in AID-induced c-myc-Igh translocations.
Nature 2006;440(7080):105-9. doi: 10.1038/nature04495
- [11] Dorsett Y, Robbiani DF, Jankovic M, Reina-San-Martin
B, Eisenreich TR, Nussenzweig MC. A role for AID in
chromosome translocations between c-myc and the IgH
variable region. J Exp Med 2007;204:2225-32. doi: 10.1084/
jem.20070884
- [12] Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required
for germinal center-derived lymphomagenesis. Nat Genet
2008;40:108-12. doi: 10.1038/ng.2007.35
- [13] Liu M, Duke JL, Richter DJ, et al. Two levels of protection
for the B cell genome during somatic hypermutation. Nature
2008;451(7180):841-5. doi: 10.1038/nature06547
- [14] Liu M, Schatz DG. Balancing AID and DNA repair during
somatic hypermutation. Trends Immunol 2009;30:173-81.
doi: 10.1016/j.it.2009.01.007
- [15] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision
of the World Health Organization classification of lymphoid
neoplasms. Blood 2016;127:2375-90. doi: 10.1182/
blood-2016-01-643569
- [16] Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation
of the molecular classification of diffuse large B-cell lymphoma
by immunohistochemistry using a tissue microarray. Blood
2004;103:275-82. doi: 10.1182/blood-2003-05-1545
- [17] López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large
B-cell lymphoma: clinical and biological characterization and
outcome according to the nodal or extranodal primary origin.
J Clin Oncol 2005;23:2797-804. doi: 10.1200/JCO.2005.07.155
- [18] Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal
involvement are prognostic in patients with diffuse large
B-cell lymphoma in the rituximab era: an analysis of the
Surveillance, Epidemiology and End Results database. Am J
Hematol 2014;89:310-4. doi: 10.1002/ajh.23638
- [19] Moller MB, Pedersen NT, Christensen BE. Diffuse large
B-cell lymphoma: clinical implications of extranodal versus
nodal presentation—a population-based study of 1575
cases. Br J Haematol 2004;124:151-9. doi: 10.1046/j.1365-
2141.2003.04749.x
- [20] Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large
B-cell lymphoma: clinical and biological characterization and
outcome according to the nodal or extranodal primary origin.
J Clin Oncol 2005;23:2797-804. doi: 10.1200/JCO.2005.07.155
- [21] Hui D, Proctor B, Donaldson J, et al. Prognostic implications
of extranodal involvement in patients with diffuse large B-cell
lymphoma treated with rituximab and cyclophosphamide,
doxorubicin, vincristine, and prednisone. Leuk Lymphoma
2010;51:1658-67. doi: 10.3109/10428.194.2010.504872
- [22] Armitage JO. A clinical evaluation of the International
Lymphoma Study Group classification of non-Hodgkin’s
lymphoma. Blood 1997;89:3909-18. doi: 10.1182/blood.
V89.11.3909
- [23] Diebold J, Anderson JR, Armitage JO, et al. Diffuse large B-cell
lymphoma: a clinicopathologic analysis of 444 cases classified
according to the updated Kiel classification. Leuk Lymphoma
2002;43:97-104. doi: 10.1080/104.281.90210173
- [24] Carella AM, de Souza CA, Luminari S, et al. Prognostic
role of gender in diffuse large B-cell lymphoma treated
with rituximab containing regimens: a Fondazione Italiana
Linfomi/Grupo de Estudos em Molestias Onco-Hematologicas
retrospective study. Leuk Lymphoma 2013;54:53-7. doi:
10.3109/10428.194.2012.691482
- [25] Pregno P, Chiappella A, Bellò M, et al. Interim 18-FDGPET/
CT failed to predict the outcome in diffuse large
B-cell lymphoma patients treated at the diagnosis with
rituximab-CHOP. Blood 2012;119:2066-73. doi: 10.1182/
blood-2011-06-359943
- [26] Le Guyader-Peyrou S, Orazio S, Dejardin O, Maynadie M,
Troussard X, Monnereau A. Factors related to the relative
survival of patients with diffuse large B-cell lymphoma in a
population-based study in France: does socio-economic status
have a role? Haematologica 2017;102:584-92. doi: 10.3324/
haematol.2016.152918
- [27] Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced
International Prognostic Index (NCCN-IPI) for patients with
diffuse large B-cell lymphoma treated in the rituximab era.
Blood 2014;123:837-42. doi: 10.1182/blood-2013-09-524108
- [28] Sehn LH, Berry B, Chhanabhai M, et al. The revised
International Prognostic Index (R-IPI) is a better predictor of
outcome than the standard IPI for patients with diffuse large
B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-
61. doi: 10.1182/blood-2006-08-038257
- [29] Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse
large B-cell lymphoma identified by gene expression profiling.
Nature 2000;403(6769):503-11. doi: 10.1038/35000501
- [30] Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers
CR. Evaluating cell-of-origin subtype methods for predicting
diffuse large B-cell lymphoma survival: a meta-analysis
of gene expression profiling and immunohistochemistry
algorithms. Clin Lymphoma Myeloma Leuk 2014;14:460-7 e2.
doi: 10.1016/j.clml.2014.05.002
- [31] Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et
al. Gene-expression profiling and not immunophenotypic
algorithms predicts prognosis in patients with diffuse large
B-cell lymphoma treated with immunochemotherapy. Blood
2011;117:4836-43. doi: 10.1182/blood-2010-12-322362
- [32] Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R,
et al. Rearrangement of MYC is associated with poor prognosis
in patients with diffuse large B-cell lymphoma treated in the
era of rituximab. J Clin Oncol 2010;28:3360-5. doi: 10.1200/
JCO.2009.26.3947
- [33] Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology
but not the immunohistochemical GCB/nonGCB classifier
predicts outcome in diffuse large B-cell lymphoma in the
RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916-25.
doi: 10.1182/blood-2010-03-276766
- [34] Hong J, Park S, Park J, et al. CD99 expression and newly
diagnosed diffuse large B-cell lymphoma treated with
rituximab-CHOP immunochemotherapy. Annals Hematol
2012;91:1897-906. doi: 10.1007/s00277.012.1533-z
- [35] Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of
immunohistochemical biomarkers in diffuse large B‐cell
lymphoma in the rituximab era. Cancer Sci 2009;100:1842-7.
doi: 10.1111/j.1349-7006.2009.01268.x
- [36] Stavnezer J. Complex regulation and function of activationinduced
cytidine deaminase. Trends Immunol 2011;32:194-
201. doi: 10.1016/j.it.2011.03.003
- [37] Willenbrock K, Renne C, Rottenkolber M, et al. The
expression of activation induced cytidine deaminase in
follicular lymphoma is independent of prognosis and
stage. Histopathology 2009;54:509-12. doi: 10.1111/j.1365-
2559.2009.03241.x
- [38] Shi Y, Zhao X, Durkin L, Rogers HJ, Hsi ED. Aberrant
activation-induced cytidine deaminase expression in
Philadelphia chromosome-positive B-cell acute lymphoblastic
leukemia. Hum Pathol 2016;52:173-8. doi: 10.1016/j.
humpath.2016.01.008
- [39] Lossos IS, Levy R, Alizadeh AA. AID is expressed in
germinal center B-cell-like and activated B-cell-like diffuse
large-cell lymphomas and is not correlated with intraclonal
heterogeneity. Leukemia 2004;18:1775-9. doi: 10.1038/
sj.leu.2403488
- [40] Greeve J, Philipsen A, Krause K, et al. Expression of
activation-induced cytidine deaminase in human B-cell non-
Hodgkin lymphomas. Blood 2003;101:3574-80. doi: 10.1182/
blood-2002-08-2424
- [41] Engels K, Jungnickel B, Tobollik S, Hansmann M L, Kriener
S, Willenbrock K. Expression of activation-induced cytidine
deaminase in malignant lymphomas infiltrating the bone
marrow. Appl Immunohisto M M 2008;16:521-9. doi: 10.1097/
PAI.0b013e3181758ce5
- [42] Gu X, Booth CJ, Liu Z, Strout MP. AID-associated DNA repair
pathways regulate malignant transformation in a murine
model of BCL6-driven diffuse large B-cell lymphoma. Blood
2016;127:102-12. doi: 10.1182/blood-2015-02-628164
- [43] Rossi D, Rasi S, Di Rocco A, et al. The host genetic
background of DNA repair mechanisms is an independent
predictor of survival in diffuse large B-cell lymphoma. Blood
2011;117:2405-13. doi: 10.1182/blood-2010-07-296244
- [44] Couronne L, Ruminy P, Waultier-Rascalou A, et al.
Mutation mismatch repair gene deletions in diffuse large
B-cell lymphoma. Leuk Lymphoma 2013;54:1079-86. doi:
10.3109/10428.194.2012.739687
- [45] Lu TX, Young KH, Xu W, Li JY. TP53 dysfunction in diffuse
large B-cell lymphoma. Crit Rev Oncol Hematol 2016;97:47-
55. doi: 10.1016/j.critrevonc.2015.08.006
- [46] Wang XJ, Medeiros LJ, Bueso-Ramos CE, et al. P53 expression
correlates with poorer survival and augments the negative
prognostic effect of MYC rearrangement, expression or
concurrent MYC/BCL2 expression in diffuse large B-cell
lymphoma. Mod Pathol 2017;30:194-203. doi: 10.1038/
modpathol.2016.178
- [47] Li S, Weiss VL, Wang XJ, et al. High-grade B-cell lymphoma
with MYC rearrangement and without BCL2 and BCL6
rearrangements is associated with high P53 expression and
a poor prognosis. Am J Surg Pathol 2016;40:253-61. doi:
10.1097/PAS.000.000.0000000542
- [48] Tessoulin B, Eveillard M, Lok A, et al. p53 dysregulation in
B-cell malignancies: More than a single gene in the pathway to
hell. Blood Rev 2017;31:251-9. doi: 10.1016/j.blre.2017.03.001
- [49] Fiskvik I, Beiske K, Delabie J, et al. Combining MYC, BCL2 and
TP53 gene and protein expression alterations improves risk
stratification in diffuse large B-cell lymphoma. Leuk Lymphoma
2015;56:1742-9. doi: 10.3109/10428.194.2014.970550
- [50] Schiefer AI, Kornauth C, Simonitsch-Klupp I, et al. Impact
of single or combined genomic alterations of TP53, MYC,
and BCL2 on survival of patients with diffuse large B-cell
lymphomas: A retrospective cohort study. Medicine (Baltimore)
2015;94:e2388. doi: 10.1097/MD.000.000.0000002388